BioWorld MedTech

March 26, 2013

Deals roundup: Argon to acquire Angiotech interventional unit for $362M

In a move to perhaps eliminate a significant portion of its debt, Angiotech Pharmaceuticals (Vancouver, British Columbia) reported the sale of its interventional products business to Argon Medical Devices (Plano, Texas) for $362.5 million. Read More

Third Rock raises $516M in oversubscribed Fund III

Financings roundup: Bausch + Lomb files IPO registration statement

Washington roundup: FDA warning to Stryker offers no insight into Neptune recall

International report: Stereotaxis receives regulatory approval of Niobe tech in Japan

Agreements/contracts: Aerocrine, Medisoft agree to licensing settlement terms

Court report: BCBSM files motion to dismiss antitrust lawsuit filed against it

Grants roundup: Stanford pediatric cancer study receives funding

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...